MTAP and lymphoma: TNG908 demonstrated selectivity and efficacy in about 200 cancer cell lines with MTAP deletion independent of their histology (cancers of bladder, CNS breast, heat and neck, pancreas, lung, gastric, uterine as well as mesothelioma, sarcoma, melanoma, leukemia and lymphoma).